Wegovy maker's board shaken up as directors quit

Novo Nordisk, maker of Wegovy and Ozempic, faces a board shakeup as several directors, including the chairman and vice chair, step down after a disagreement with the company's majority shareholder, the Novo Nordisk Foundation. The move comes amid financial challenges, including a profit warning and increased competition from US rivals like Eli Lilly. The Foundation, which holds significant voting rights, is seeking changes in company governance and strategic direction, reflecting tensions over the firm's response to market shifts affecting its diabetes and weight loss drugs.